Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Yoshihiko TasakiShuzo HamamotoYosuke SugiyamaNami TomiyamaTaku NaikiToshiki EtaniKazumi TaguchiNayuka MatsuyamaYasuhito SueYoshihisa MimuraHiroki KubotaYusuke NodaMaria AokiYoshinobu MoritokiSatoshi NozakiSatoshi KurokawaAtsushi OkadaNoriyasu KawaiTakahiro YasuiKazunori KimuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2023)
An increased eosinophil level 2 weeks after treatment might be an effective biomarker for ≥grade 2 irAEs in patients with RCC treated with ipilimumab and nivolumab.